Imagine a high-tech GPS for germs that tells us exactly where a disease is moving and how it's changing. By reading the genetic code of bacteria and parasites, scientists can spot when medicines stop working before it becomes a crisis. It's like having an early warning system to stop outbreaks in their tracks.
African health systems struggle with fragmented data and limited genomic capacity, making it difficult to track drug-resistant TB and malaria or respond quickly to new pathogens.
Developed SeqSphere+ software for core genome MLST analysis and established standard operating protocols for next-generation sequencing and bioinformatics.
If you are a medical device manufacturer dealing with outdated TB tests — this project developed genomic data on drug-resistant strains that allows for the creation of more sensitive and specific rapid diagnostics.
If you are an antimalarial drug developer dealing with emerging drug resistance — this project developed a regional surveillance system that provides pre-emptive detection of resistant parasites to guide R&D.
If you are a health data software provider dealing with fragmented African health data — this project developed SeqSphere+ and harmonized analysis tools to identify cross-border spread of pathogens.
Based on available project data, there is no information regarding the cost or pricing of the developed tools.
The project is currently in the proof-of-concept stage, focusing on establishing infrastructure and training across 11 countries to build capacity for future scaling.
Based on available project data, specific IP or licensing terms for SeqSphere+ and other tools are not mentioned.
The project focuses on creating harmonized genomic data analysis tools and biobanking to allow for continent-wide surveillance networks.
The project period runs from 2023-07-01 to 2027-06-30, with initial workshops and infrastructure assessments completed in 2024.
The consortium is heavily research-oriented, consisting of 13 partners from 11 countries, including 7 research institutes and 5 universities. There are 0 industry partners and 0 SMEs, indicating that the project is currently in a pre-commercial, academic phase focused on capacity building and infrastructure in Africa.
Contact Forschungszentrum Borstel Leibniz Lungenzentrum in Germany.
Contact us to explore licensing opportunities for SeqSphere+ or genomic data partnerships.
